Search

Your search keyword '"John C. O'Donnell"' showing total 2 results
Start Over Author "John C. O'Donnell" Publisher future medicine ltd
2 results on '"John C. O'Donnell"'

1. Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study

Author

Ariadna Juarez-Garcia, John C O'Donnell, John R. Penrod, Mats Rosenlund, Simon Ekman, Jens Benn Sørensen, Anne Mette Kejs, Pia Horvat, L. Lacoin, Odd Terje Brustugun, Dony Patel, and M. Daumont

Subjects
Male, Oncology, Cancer Research, Lung Neoplasms, I-O Optimise initiative, Denmark, medicine.medical_treatment, registry, NSCLC, Tyrosine-kinase inhibitor, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Pneumonectomy, Lung, treatment, General Medicine, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Female, Non small cell, Adult, medicine.medical_specialty, Adolescent, medicine.drug_class, overall survival, Stage iv disease, History, 21st Century, Young Adult, Internal medicine, medicine, Overall survival, Humans, Initial treatment, In patient, Mortality, Lung cancer, Aged, Neoplasm Staging, Retrospective Studies, time trends, business.industry, Chemoradiotherapy, Adjuvant, medicine.disease, respiratory tract diseases, Radiation therapy, SCAN-LEAF, business, Follow-Up Studies
Abstract

Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005–2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0–60.6%) but not squamous NSCLC (44.9–47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23–31%) but not squamous NSCLC (22–25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.

Published
2022

2. Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database

Author

Luís Antunes, Maria José Bento, Melinda Daumont, Ruben Hermans, Marta C. Soares, Marina Borges, Dony Patel, Patrícia Redondo, John C O'Donnell, L. Lacoin, Francisco Rocha Gonçalves, Fiona Grimson, C. Chaib, John R. Penrod, and Robin E.J. Munro

Subjects
Pulmonary and Respiratory Medicine, Oncology, squamous cell carcinoma, medicine.medical_specialty, medicine.medical_treatment, overall survival, Stage ii, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Stage IIIA NSCLC, medicine, Retrospective analysis, 030212 general & internal medicine, Stage (cooking), Lung cancer, real-world evidence, business.industry, stage I–IIIA, Histology, medicine.disease, non-squamous cell carcinoma, respiratory tract diseases, Radiation therapy, non-small-cell lung cancer, treatment patterns, 030220 oncology & carcinogenesis, Non small cell, business, Research Article
Abstract

Aim: This observational study evaluated treatment patterns and survival for patients with stage I–IIIA non-small-cell lung cancer (NSCLC). Materials & methods: Adults newly diagnosed with NSCLC in 2012–2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015–2016. Results: 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012–2016) were 92% (88–96), 71% (62–82) and 69% (63–75), respectively; one-year OS (95% CI) for treated patients with stage I–II or stage IIIA NSCLC (diagnosed 2015–2016) were 89% (81–97) and 86% (75–98) for non-squamous cell and 76% (60–95) and 49% (34–70) for squamous cell NSCLC. Conclusion: Treatment advances are strongly needed for stage I–IIIA NSCLC, especially for patients with squamous cell histology.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results